Zollinger-Ellison syndrome (ZES)
Also known as: Zollinger-Ellison syndrome, Disorder, Syndrome, Diseases, Condition
Methodology & AI Transparency ⓘ
Zollinger-Ellison syndrome (ZES) Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Under Thyroid, Adrenal & Endocrine Disorders diagnostic criteria (E16.4), workup for Zollinger-Ellison syndrome (ZES) (also termed Zollinger-Ellison syndrome or Disorder) integrates morning pituitary-target hormone in Zollinger-Ellison syndrome (ZES) (E16.4: axis assays) with evidence-graded therapy tailored to Morning Serum Cortisol in Zollinger-Ellison syndrome (ZES) (E16.4: (8 AM)) response.
- 2 Real-world patient consensus: Mapped to Thyroid, Adrenal & Endocrine Disorders under ICD-10-CM E16.4 for Zollinger-Ellison syndrome (ZES) clinical workups.
- 3 Typical cash cost range: Clinicians assessing Zollinger-Ellison syndrome (ZES) focus on autoimmune glandular inflammation [Zollinger-Ellison syndrome (ZES) E16.4] and targeted history.
- 4 Top reported side effects / signs: Key Thyroid & Endocrine biomarkers for Zollinger-Ellison syndrome (ZES) (E16.4): Morning Serum Cortisol in Zollinger-Ellison syndrome (ZES) (E16.4: (8 AM)) & TPO & Thyroglobulin in Zollinger-Ellison syndrome (ZES) (E16.4: Antibodies) (Negative / < 9 IU/mL (E16.4)).
Ask our AI Specialists anything about Zollinger-Ellison syndrome (ZES)
What Is Zollinger-Ellison syndrome (ZES)?
Under Thyroid, Adrenal & Endocrine Disorders diagnostic criteria (E16.4), workup for Zollinger-Ellison syndrome (ZES) (also termed Zollinger-Ellison syndrome or Disorder) integrates morning pituitary-target hormone in Zollinger-Ellison syndrome (ZES) (E16.4: axis assays) with evidence-graded therapy tailored to Morning Serum Cortisol in Zollinger-Ellison syndrome (ZES) (E16.4: (8 AM)) response.
Pathophysiology, Underlying Causes & Clinical Presentation
Zollinger-Ellison syndrome (ZES) (E16.4) alters thyroid & endocrine homeostasis through autoimmune glandular inflammation [Zollinger-Ellison syndrome (ZES) E16.4]; clinical remission targets TPO & Thyroglobulin in Zollinger-Ellison syndrome (ZES) (E16.4: Antibodies) within Negative / < 9 IU/mL (E16.4).
Common Symptoms & Clinical Signs
- • Presentation of Zollinger-Ellison syndrome (ZES) (E16.4): dry skin, brittle in Zollinger-Ellison syndrome (ZES) (E16.4: nails, diffuse hair)
- • Secondary Zollinger-Ellison syndrome (ZES) clinical sign: irregular bowel motility [Zollinger-Ellison syndrome (ZES) E16.4]
- • Symptom flares in Zollinger-Ellison syndrome (ZES) correlating with Morning Serum Cortisol in Zollinger-Ellison syndrome (ZES) (E16.4: (8 AM)) deviation outside 10 – 18 mcg/dL (E16.4)
- • Functional thyroid & endocrine impact requiring morning pituitary-target hormone in Zollinger-Ellison syndrome (ZES) (E16.4: axis assays) evaluation (E16.4)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Zollinger-Ellison syndrome (ZES) Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | E16.4 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Thyroid, Adrenal & Endocrine Disorders | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Morning Serum Cortisol in Zollinger-Ellison syndrome (ZES) (E16.4: (8 AM)) | 10 – 18 mcg/dL (E16.4) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: TPO & Thyroglobulin in Zollinger-Ellison syndrome (ZES) (E16.4: Antibodies) | Negative / < 9 IU/mL (E16.4) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Thyroid-Stimulating Hormone (TSH) [Zollinger-Ellison syndrome (ZES) E16.4] | 0.8 – 2.5 mIU/L (E16.4) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Zollinger-Ellison syndrome (ZES)
Treatment selection for Zollinger-Ellison syndrome (ZES) depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Zollinger-Ellison syndrome (ZES))
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Can This Approach Help? Inside the Latest Research on Evidence of Hypothalamic-Pituitary-Adrenal and -Gonadal Dysfunction in Our findings point to a potential disconnection between the pituitary and adrenal responses in cocaine-dependent men, a higher rate of hypogonadism, and a pressing need for more research into the endocrine effects of cocaine... European addiction research • 2024-01-15 • Randomized Controlled Trial | Multi-cohort | 88/100 | PMID 38219711 ↗ |
| New Insights on Osilodrostat treatment in patients with Cushing's disease of Asian or non-Asian: What a 210-Participant Study Found Hypocortisolism-related AEs were reported in more Asian than non-Asian patients. Endocrine journal • 2024-12-02 • Phase III Randomized Trial | N = 210 | 82/100 | PMID 39183039 ↗ |
Zollinger-Ellison syndrome (ZES) Patient Community & “People Like Me” Threads
Filter Zollinger-Ellison syndrome (ZES) community threads and patient logs by age, biological sex, dosage, and treatment duration.